xanthurenic acid has been researched along with Schizophrenia in 7 studies
xanthurenic acid : A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by hydroxy groups at C-4 and C-8.
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aim & Objective: To delineate the associations between executive impairments and changes in tryptophan catabolite (TRYCAT) patterning, negative symptoms and deficit schizophrenia." | 7.88 | The Effects of Tryptophan Catabolites on Negative Symptoms and Deficit Schizophrenia are Partly Mediated by Executive Impairments: Results of Partial Least Squares Path Modeling. ( Kanchanatawan, B; Maes, M, 2018) |
| "Deficit schizophrenia is accompanied by mucosa-associated activation of the tryptophan catabolite (TRYCAT) pathway, as indicated by increased IgA responses to noxious (NOX) TRYCATs, but not regulatory or protective (PRO) TRYCATs, suggesting increased neurotoxic, excitotoxic, inflammatory, and oxidative potential." | 7.88 | Deficit Schizophrenia Is Characterized by Defects in IgM-Mediated Responses to Tryptophan Catabolites (TRYCATs): a Paradigm Shift Towards Defects in Natural Self-Regulatory Immune Responses Coupled with Mucosa-Derived TRYCAT Pathway Activation. ( Anderson, G; Carvalho, AF; Geffard, M; Kanchanatawan, B; Maes, M; Ruxrungtham, K; Sirivichayakul, S, 2018) |
| "The kynurenine pathway of tryptophan metabolism has been implicated in the pathophysiology of psychiatric disorders, including schizophrenia." | 7.81 | Xanthurenic Acid Activates mGlu2/3 Metabotropic Glutamate Receptors and is a Potential Trait Marker for Schizophrenia. ( Battaglia, G; Bruno, V; Capi, M; Caruso, A; Cavallari, M; Comparelli, A; Corigliano, V; Curto, M; De Blasi, A; De Carolis, A; De Fusco, A; Di Menna, L; Fazio, F; Girardi, P; Gradini, R; Iacovelli, L; Lionetto, L; Miele, J; Napoletano, F; Nicoletti, F; Nisticò, R; Scaccianoce, S; Simmaco, M; Ulivieri, M; Zappulla, C, 2015) |
| "Primary deficit schizophrenia is accompanied by an activated TRYCAT pathway as compared to controls and nondeficit schizophrenia." | 5.48 | Deficit, but Not Nondeficit, Schizophrenia Is Characterized by Mucosa-Associated Activation of the Tryptophan Catabolite (TRYCAT) Pathway with Highly Specific Increases in IgA Responses Directed to Picolinic, Xanthurenic, and Quinolinic Acid. ( Anderson, G; Carvalho, AF; Geffard, M; Kanchanatawan, B; Maes, M; Ormstad, H; Ruxrungtham, K; Sirivichayakul, S, 2018) |
| " Herein we examined the effects of immune activation in association with tryptophan catabolite (TRYCAT) patterning and memory disorders on PHEMN/DAPS dimensions and MNP." | 3.91 | A New Schizophrenia Model: Immune Activation is Associated with the Induction of Different Neurotoxic Products which Together Determine Memory Impairments and Schizophrenia Symptom Dimensions. ( Carvalho, AF; Kanchanatawan, B; Maes, M; Sirivichayakul, S; Thika, S, 2019) |
| "Aim & Objective: To delineate the associations between executive impairments and changes in tryptophan catabolite (TRYCAT) patterning, negative symptoms and deficit schizophrenia." | 3.88 | The Effects of Tryptophan Catabolites on Negative Symptoms and Deficit Schizophrenia are Partly Mediated by Executive Impairments: Results of Partial Least Squares Path Modeling. ( Kanchanatawan, B; Maes, M, 2018) |
| "Deficit schizophrenia is accompanied by mucosa-associated activation of the tryptophan catabolite (TRYCAT) pathway, as indicated by increased IgA responses to noxious (NOX) TRYCATs, but not regulatory or protective (PRO) TRYCATs, suggesting increased neurotoxic, excitotoxic, inflammatory, and oxidative potential." | 3.88 | Deficit Schizophrenia Is Characterized by Defects in IgM-Mediated Responses to Tryptophan Catabolites (TRYCATs): a Paradigm Shift Towards Defects in Natural Self-Regulatory Immune Responses Coupled with Mucosa-Derived TRYCAT Pathway Activation. ( Anderson, G; Carvalho, AF; Geffard, M; Kanchanatawan, B; Maes, M; Ruxrungtham, K; Sirivichayakul, S, 2018) |
| "The kynurenine pathway of tryptophan metabolism has been implicated in the pathophysiology of psychiatric disorders, including schizophrenia." | 3.81 | Xanthurenic Acid Activates mGlu2/3 Metabotropic Glutamate Receptors and is a Potential Trait Marker for Schizophrenia. ( Battaglia, G; Bruno, V; Capi, M; Caruso, A; Cavallari, M; Comparelli, A; Corigliano, V; Curto, M; De Blasi, A; De Carolis, A; De Fusco, A; Di Menna, L; Fazio, F; Girardi, P; Gradini, R; Iacovelli, L; Lionetto, L; Miele, J; Napoletano, F; Nicoletti, F; Nisticò, R; Scaccianoce, S; Simmaco, M; Ulivieri, M; Zappulla, C, 2015) |
| "Primary deficit schizophrenia is accompanied by an activated TRYCAT pathway as compared to controls and nondeficit schizophrenia." | 1.48 | Deficit, but Not Nondeficit, Schizophrenia Is Characterized by Mucosa-Associated Activation of the Tryptophan Catabolite (TRYCAT) Pathway with Highly Specific Increases in IgA Responses Directed to Picolinic, Xanthurenic, and Quinolinic Acid. ( Anderson, G; Carvalho, AF; Geffard, M; Kanchanatawan, B; Maes, M; Ormstad, H; Ruxrungtham, K; Sirivichayakul, S, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kanchanatawan, B | 4 |
| Maes, M | 4 |
| Sirivichayakul, S | 3 |
| Thika, S | 1 |
| Carvalho, AF | 3 |
| Curto, M | 2 |
| Lionetto, L | 2 |
| Fazio, F | 2 |
| Corigliano, V | 2 |
| Comparelli, A | 2 |
| Ferracuti, S | 1 |
| Simmaco, M | 2 |
| Nicoletti, F | 2 |
| Baldessarini, RJ | 1 |
| Oxenkrug, G | 1 |
| Bernstein, HG | 1 |
| Guest, PC | 1 |
| van der Hart, M | 1 |
| Roeser, J | 1 |
| Summergrad, P | 1 |
| Steiner, J | 1 |
| Iacovelli, L | 1 |
| Cavallari, M | 1 |
| Zappulla, C | 1 |
| Ulivieri, M | 1 |
| Napoletano, F | 1 |
| Capi, M | 1 |
| Scaccianoce, S | 1 |
| Caruso, A | 1 |
| Miele, J | 1 |
| De Fusco, A | 1 |
| Di Menna, L | 1 |
| De Carolis, A | 1 |
| Gradini, R | 1 |
| Nisticò, R | 1 |
| De Blasi, A | 1 |
| Girardi, P | 1 |
| Bruno, V | 1 |
| Battaglia, G | 1 |
| Ruxrungtham, K | 2 |
| Geffard, M | 2 |
| Ormstad, H | 1 |
| Anderson, G | 2 |
7 other studies available for xanthurenic acid and Schizophrenia
| Article | Year |
|---|---|
The Effects of Tryptophan Catabolites on Negative Symptoms and Deficit Schizophrenia are Partly Mediated by Executive Impairments: Results of Partial Least Squares Path Modeling.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Cognition Disorders; Executive Function; Female; Huma | 2018 |
A New Schizophrenia Model: Immune Activation is Associated with the Induction of Different Neurotoxic Products which Together Determine Memory Impairments and Schizophrenia Symptom Dimensions.
Topics: Anxiety; Anxiety Disorders; Humans; Memory Disorders; Neuropsychological Tests; Schizophrenia; Trypt | 2019 |
Serum xanthurenic acid levels: Reduced in subjects at ultra high risk for psychosis.
Topics: Adolescent; Adult; Disease Progression; Female; Humans; Hydroxyindoleacetic Acid; Kynurenic Acid; Ky | 2019 |
Plasma xanthurenic acid in a context of insulin resistance and obesity in schizophrenia.
Topics: Case-Control Studies; Humans; Insulin Resistance; Kynurenic Acid; Kynurenine; Obesity; Schizophrenia | 2019 |
Xanthurenic Acid Activates mGlu2/3 Metabotropic Glutamate Receptors and is a Potential Trait Marker for Schizophrenia.
Topics: Adult; Aged; Animals; Biomarkers; Brain; Case-Control Studies; Female; HEK293 Cells; Humans; Kynuren | 2015 |
Deficit, but Not Nondeficit, Schizophrenia Is Characterized by Mucosa-Associated Activation of the Tryptophan Catabolite (TRYCAT) Pathway with Highly Specific Increases in IgA Responses Directed to Picolinic, Xanthurenic, and Quinolinic Acid.
Topics: Adult; Cross-Sectional Studies; Female; Humans; Immunoglobulin A; Inflammation; Male; Middle Aged; P | 2018 |
Deficit Schizophrenia Is Characterized by Defects in IgM-Mediated Responses to Tryptophan Catabolites (TRYCATs): a Paradigm Shift Towards Defects in Natural Self-Regulatory Immune Responses Coupled with Mucosa-Derived TRYCAT Pathway Activation.
Topics: Adult; Biomarkers; Female; Humans; Immunity, Cellular; Immunoglobulin M; Kynurenic Acid; Male; Metab | 2018 |